Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 5/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9844635 | 0.90 | OPRM1 (0.48) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL16930985 | 0.90 | OPRM1 (0.48) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL31549909 | 0.90 | DNM1 (0.38) | OPRM1FAAHCNR1CNR2LMNA | |
| SCHEMBL30450150 | 0.90 | OPRM1 (0.48) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL15657362 | 0.89 | FAAH (0.40) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL15659876 | 0.89 | FAAH (0.40) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL15658713 | 0.89 | FAAH (0.40) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL15659844 | 0.89 | FAAH (0.40) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL15656990 | 0.89 | FAAH (0.40) | OPRM1FAAHCNR1CNR2SPHK1 | |
| SCHEMBL15658556 | 0.89 | FAAH (0.40) | OPRM1FAAHCNR1CNR2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372430-B2 | comprises stiffening agents for ameliorating side effects associated with adminstration of lipase inhibitors (anal leakage of undigested fat or oil); for treatment of diabetes | THE PROCTER & GAMBLE COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1572240-A1 | COMPOSITIONS, METHODS, AND KITS USEFUL FOR THE ALLEVIATION OF GASTROINTESTINAL SIDE EFFECTS OF LIPASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004060401-A1 | COMPOSITIONS, METHODS, AND KITS USEFUL FOR THE ALLEVIATION OF GASTROINTESTINAL SIDE EFFECTS OF LIPASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040126424-A1 | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects | JANDACEK RONALD JAMES (US) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040126424-A1 | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects | PNLIP, LIPC, LIPA | OPRM1 2398/4885FAAH 57/4885CNR1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.